| 초록 |
Bone morphogenic protein-2 (BMP-2) is the most notable growth factor in the field of bone regeneration, and is clinically used in various techniques such as maxillary bone grafting and bone induction regeneration. The delivery protocol currently approved by the Food and Drug Administration (FDA, USA) is to contain biphasic calcium phosphate (BCP) in a BMP-2 solution. However, using this method, the delivery of BMP-2 is irregular and uncontrolled, with most of the BMP-2 loaded on BCP being over-emitted after transplantation and the clinical use is limited. In this study, the release of optimized growth factors and antibiotics was confirmed by using gelatin microspheres (GMSs) with different degradation rates to block-type BCP, and the efficacy was evaluated by applying them to animal models. We intend to precisely regulate the timing, rate, and capacity of release of BMP-2 to apply more diverse concentrations of BMP-2 in horizontal bone defects and longer release during bone regeneration. |
